CLEOCIN INJECTION Rx
Generic Name and Formulations:
Clindamycin (as phosphate) 150mg/mL; contains benzyl alcohol.
Indications for CLEOCIN INJECTION:
Serious susceptible infections where less toxic antibiotics are inappropriate, including respiratory, skin and soft tissue, septicemia, intraabdominal, female pelvic or genital; bone and joint (inj).
Serious: 0.6–1.2g daily. More severe: 1.2–2.7g/day IM or IV. Both: give in 2–4 equally divided doses; max 600mg per IM inj and 4.8g/day IV. Beta-hemolytic streptococcal infections: treat for at least 10 days.
Neonates: 15–20mg/kg per day. >1 month: 20–40mg/kg per day IM or IV. Both: give in 3–4 equally divided doses. Or: serious infections: 350mg/m2 per day; more severe: 450mg/m2 per day. Beta-hemolytic streptococcal infections: treat for at least 10 days.
Not for treatment of meningitis. Discontinue if colitis occurs and treat. Permanently discontinue if severe hypersensitivity reactions occur. Allergy. Asthma (75mg, 150mg caps). GI disease (esp. colitis). Atopy. Monitor blood, renal, and hepatic function in long-term use and in children. IV: Gasping syndrome (neonates, infants). Elderly. Pregnancy. Nursing mothers: consider alternative drug.
May potentiate neuromuscular blocking agents; caution. May be potentiated by strong CYP3A4 inhibitors; monitor. May be antagonized by strong CYP3A4 inducers (eg, rifampicin); monitor. May antagonize erythromycin; avoid. Antiperistaltic agents may worsen colitis.
Pseudomembranous colitis, C. difficile-associated diarrhea, nausea, vomiting, abdominal pain, dysguesia, rash, pruritus, angioedema, anaphylaxis, jaundice, renal dysfunction, blood dyscrasias, polyarthritis, severe skin reactions (eg, toxic epidermal necrolysis, erythema multiforme, drug reaction with eosinophilia and systemic symptoms, Stevens-Johnson syndrome).
Caps—100; Granules (100mL)—1; Inj (2mL, 4mL, 6mL vials)—25
Sign Up for Free e-newsletters
- Chemotherapy-Related Fatigue Linked to Levothyroxine Use in Breast Cancer
- New Hypertension Threshold Guides Blood Pressure Management During Cancer Treatment
- Sexual Aids and Resources Not Readily Available at Cancer Centers
- Factors Affecting Employment Participation in Early-stage Breast Cancer
- Gas Mixture Improves Efficacy of Breakthrough Cancer Pain Treatment
- Sitting With Silence in End-of-Life Cancer Care
- Obesity and Cancer Risk (Fact Sheet)
- Susceptibility Gene Mutations Common in Those With Pancreatic Cancer and History of Other Cancers
- Anticancer Properties of Omega-3 Fatty Acids: Plant-Based vs Marine-Based
- US Pharmacopeia Revises Chapter on Handling Hazardous Drugs
- Follow-Up After Treatment Lacking for Younger Cancer Survivors
- Adjuvant Vemurafenib Does Not Improve Disease-Free Survival in Melanoma
- Profile of Buparlisib and its Potential in the Treatment of Breast Cancer: Evidence to Date
- Exercise Before Lung Cancer Surgery Greatly Reduces Complications
- Hodgkin Lymphoma Treatment in EU vs US: Similarities Would Enable Worldwide Studies
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|